Electronic vape fluid activates the pulmonary endothelium and disrupts vascular integrity in vitro through an ARF6-dependent pathway
Microvascular Research · 2024-05 · 153 · 104653
DOI: 10.1016/j.mvr.2024.104653 ↗At a glance
Journal article in Microvascular Research, 2024-05. Written by Evangelene Blackham-Hayward and 2 co-authors. Institution: Biomedical Research Group, Anglia Ruskin University, Cambridge, UK. Major MEDLINE topics: Electronic Nicotine Delivery Systems, Vaping, Lung Injury. Cited 10 times so far (Crossref); 72 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
The use of e-cigarettes or vapes is increasingly popular amongst a range of different demographics however the research in this area is surprisingly sparse. Clinical reports of e-cigarette- or vaping use-associated lung injury (EVALI) and vascular disruption, in both nicotine-containing and nicotine-free e-cigarette smokers, prompts the need for further research with a focus on the pulmonary endothelium. Using a common brand of e-cigarette (eVape) and an in vitro model of the human lung microvasculature, we investigated the effect of nicotine-free eVape fluid on pulmonary endothelial barrier integrity, oxidative stress and inflammation profile. Findings demonstrate reactive oxygen species-dependent breakdown of the pulmonary endothelium and release of inflammatory cytokines. These phenotypic changes, following exposure to nicotine-free eVape fluid, were accompanied by dysregulation of a number of adheren junctions-related genes of which ARF6 was most abundantly overexpressed. Further investigation of ARF6 identified it as a key regulator in eVape-induced barrier disruption and ROS accumulation. This study demonstrates, for the first time, the barrier disruptive effect of nicotine-free e-cigarette fluid on the pulmonary microvasculature and the ARF6 and ROS-dependent molecular mechanisms underlying this damage. Whilst these studies focus on a human in vitro model of the pulmonary microvasculature, the results support clinical case studies on EVALI and demonstrate a need for further investigation of the impact of nicotine-free e-cigarettes on the lung.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Biomedical Research Group, Anglia Ruskin University, Cambridge, UK.
- Biomedical Research Group, Anglia Ruskin University, Cambridge, UK. Electronic address: havovi.chichger@aru.ac.uk.
Cite
APA
Blackham-Hayward, E., Kertesz, Z., & Chichger, H. (2024). Electronic vape fluid activates the pulmonary endothelium and disrupts vascular integrity in vitro through an ARF6-dependent pathway. Microvascular Research, 153, 104653. https://doi.org/10.1016/j.mvr.2024.104653
Vancouver
Blackham-Hayward E, Kertesz Z, Chichger H. Electronic vape fluid activates the pulmonary endothelium and disrupts vascular integrity in vitro through an ARF6-dependent pathway. Microvascular Research. 2024;153:104653. doi:10.1016/j.mvr.2024.104653
BibTeX
@article{BlackhamHayward2024,
author = {Blackham-Hayward, Evangelene and Kertesz, Zsuzsanna and Chichger, Havovi},
title = {Electronic vape fluid activates the pulmonary endothelium and disrupts vascular integrity in vitro through an ARF6-dependent pathway},
journal = {Microvascular Research},
year = {2024},
volume = {153},
pages = {104653},
doi = {10.1016/j.mvr.2024.104653}
}
EUVIMED